{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:42:40Z","timestamp":1793396560574,"version":"4.5.0"},"reference-count":84,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2018,7,30]]},"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:p>The immune system has long been recognised important in pain regulation through inflammatory cytokine modulation of peripheral nociceptive fibres. Recently, cytokine interactions in brain and spinal cord glia as well as dorsal root ganglia satellite glia have been identified important\u2014 in pain modulation. The result of these interactions is central and peripheral sensitisation of nociceptive processing. Additionally, new insights and the term \u2018autoimmune pain\u2019 have emerged through discovery of specific IgGs targeting the extracellular domains of antigens at nodal and synaptic structures, causing pain directly without inflammation by enhancing neuronal excitability. Other discovered IgGs heighten pain indirectly by T-cell-mediated inflammation or destruction of targets within the nociceptive pathways. Notable identified IgGs in pain include those against the components of channels and receptors involved in inhibitory or excitatory somatosensory synapses or their pathways: nodal and paranodal proteins (LGI1, CASPR1, CASPR2); glutamate detection (AMPA-R); GABA regulation and release (GAD65, amphiphysin); glycine receptors (GLY-R); water channels (AQP4). These disorders have other neurological manifestations of central\/peripheral hyperexcitabability including seizures, encephalopathy, myoclonus, tremor and spasticity, with immunotherapy responsiveness. Other pain disorders, like complex regional pain disorder, have been associated with IgGs against \u03b22-adrenergic receptor, muscarinic-2 receptors, AChR-nicotinic ganglionic \u03b1-3 receptors and calcium channels (N and P\/Q types), but less consistently with immune treatment response. Here, we outline how the immune system contributes to development and regulation of pain, review specific IgG-mediated pain disorders and summarise recent development in therapy approaches. Biological agents to treat pain (anti-calcitonin gene-related peptide and anti-nerve growth factor) are also discussed.<\/jats:p>","DOI":"10.1136\/jnnp-2018-318556","type":"journal-article","created":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T16:18:59Z","timestamp":1537201139000},"page":"177-188","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":57,"title":["Pain and the immune system: emerging concepts of IgG-mediated autoimmune pain and immunotherapies"],"prefix":"10.1136","volume":"91","author":[{"given":"Min","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L H","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-8264","authenticated-orcid":false,"given":"Luis Antonio","family":"Querol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarosh R","family":"Irani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,9,17]]},"reference":[{"key":"2024111108000862000_91.2.177.1","unstructured":"Celsus AC . Self published. De medicina 25 AD."},{"key":"2024111108000862000_91.2.177.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.09.030"},{"key":"2024111108000862000_91.2.177.3","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200407000-00002"},{"key":"2024111108000862000_91.2.177.4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamaneurol.2017.0486","article-title":"Association of long-term opioid therapy with functional status, adverse outcomes, and mortality among patients with polyneuropathy","volume":"74","author":"Hoffman","year":"2017","journal-title":"JAMA Neurol"},{"key":"2024111108000862000_91.2.177.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2008.04.025"},{"key":"2024111108000862000_91.2.177.6","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000492"},{"key":"2024111108000862000_91.2.177.7","doi-asserted-by":"publisher","DOI":"10.1159\/000068681"},{"key":"2024111108000862000_91.2.177.8","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3144"},{"key":"2024111108000862000_91.2.177.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2010.08.013"},{"key":"2024111108000862000_91.2.177.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.06.022"},{"key":"2024111108000862000_91.2.177.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2004.12.002"},{"key":"2024111108000862000_91.2.177.12","doi-asserted-by":"publisher","DOI":"10.1038\/nature01786"},{"key":"2024111108000862000_91.2.177.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.06.018"},{"key":"2024111108000862000_91.2.177.14","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4189"},{"key":"2024111108000862000_91.2.177.15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/B978-0-444-63432-0.00023-2","article-title":"Autoimmune-mediated peripheral neuropathies and autoimmune pain","volume":"133","author":"Klein","year":"2016","journal-title":"Handb Clin Neurol"},{"key":"2024111108000862000_91.2.177.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2011.04.008"},{"key":"2024111108000862000_91.2.177.17","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1212\/WNL.0000000000004803","article-title":"Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases","volume":"90","author":"Dubey","year":"2018","journal-title":"Neurology"},{"key":"2024111108000862000_91.2.177.18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182698dc3"},{"key":"2024111108000862000_91.2.177.19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182698cab"},{"key":"2024111108000862000_91.2.177.20","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq213"},{"key":"2024111108000862000_91.2.177.21","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22297"},{"key":"2024111108000862000_91.2.177.22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ana.24979","article-title":"Expanded phenotypes and outcomes among 256 LGI1\/CASPR2-IgG-positive patients","volume":"82","author":"Gadoth","year":"2017","journal-title":"Ann Neurol"},{"key":"2024111108000862000_91.2.177.23","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23577"},{"key":"2024111108000862000_91.2.177.24","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/mus.25371","article-title":"Clinical-pathologic correlations in voltage-gated Kv1 potassium channel complex-subtyped autoimmune painful polyneuropathy","volume":"55","author":"Lahoria","year":"2017","journal-title":"Muscle Nerve"},{"key":"2024111108000862000_91.2.177.25","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1212\/WNL.0000000000002037","article-title":"Peripheral small fiber dysfunction and neuropathic pain in patients with Morvan syndrome","volume":"85","author":"Laurencin","year":"2015","journal-title":"Neurology"},{"key":"2024111108000862000_91.2.177.26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/mus.23935","article-title":"Cramp-fasciculation syndrome in patients with and without neural autoantibodies","volume":"49","author":"Liewluck","year":"2014","journal-title":"Muscle Nerve"},{"key":"2024111108000862000_91.2.177.27","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2017-315720","article-title":"LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes","volume":"89","author":"Binks","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024111108000862000_91.2.177.28","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1002\/mus.10148","article-title":"Isaacs' syndrome as a potassium channelopathy of the nerve","volume":"11","author":"Arimura","year":"2002","journal-title":"Muscle Nerve Suppl"},{"key":"2024111108000862000_91.2.177.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2018.01.033"},{"key":"2024111108000862000_91.2.177.30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00401-017-1751-5","article-title":"Persistent microglial activation and synaptic loss with behavioral abnormalities in mouse offspring exposed to CASPR2-antibodies in utero","volume":"134","author":"Coutinho","year":"2017","journal-title":"Acta Neuropathol"},{"key":"2024111108000862000_91.2.177.31","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww189"},{"key":"2024111108000862000_91.2.177.32","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000149","article-title":"Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins","volume":"2","author":"Querol","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024111108000862000_91.2.177.33","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/WNL.0000000000002418","article-title":"Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy","volume":"86","author":"Devaux","year":"2016","journal-title":"Neurology"},{"key":"2024111108000862000_91.2.177.34","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23794"},{"key":"2024111108000862000_91.2.177.35","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.322909"},{"key":"2024111108000862000_91.2.177.36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/mus.25027","article-title":"P\/Q- and N-type calcium-channel antibodies: oncological, neurological, and serological accompaniments","volume":"54","author":"Zalewski","year":"2016","journal-title":"Muscle Nerve"},{"key":"2024111108000862000_91.2.177.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2009.06.002"},{"key":"2024111108000862000_91.2.177.38","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10266"},{"key":"2024111108000862000_91.2.177.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2004.07.066"},{"key":"2024111108000862000_91.2.177.40","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn183"},{"key":"2024111108000862000_91.2.177.41","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2013.845527"},{"key":"2024111108000862000_91.2.177.42","doi-asserted-by":"crossref","DOI":"10.5334\/tohm.316","article-title":"Clinical spectrum of stiff person syndrome: a review of recent reports","volume":"6","author":"Sarva","year":"2016","journal-title":"Tremor Other Hyperkinet Mov"},{"key":"2024111108000862000_91.2.177.43","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.991"},{"key":"2024111108000862000_91.2.177.44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/mus.25565","article-title":"GAD65 neurological autoimmunity","volume":"56","author":"McKeon","year":"2017","journal-title":"Muscle Nerve"},{"key":"2024111108000862000_91.2.177.45","first-page":"237","article-title":"Stiff person syndrome and motor mononeuropathy with conduction block: a singular association","volume":"157","author":"La Spada","year":"2006","journal-title":"Clin Ter"},{"key":"2024111108000862000_91.2.177.46","doi-asserted-by":"publisher","DOI":"10.4065\/81.9.1207"},{"key":"2024111108000862000_91.2.177.47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.11.7755"},{"key":"2024111108000862000_91.2.177.48","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2442"},{"key":"2024111108000862000_91.2.177.49","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamaneurol.2013.574","article-title":"Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype","volume":"70","author":"McKeon","year":"2013","journal-title":"JAMA Neurol"},{"key":"2024111108000862000_91.2.177.50","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)81165-4"},{"key":"2024111108000862000_91.2.177.51","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awu142"},{"key":"2024111108000862000_91.2.177.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2015.02.028"},{"key":"2024111108000862000_91.2.177.53","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20529"},{"key":"2024111108000862000_91.2.177.54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66376-3"},{"key":"2024111108000862000_91.2.177.55","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.768"},{"key":"2024111108000862000_91.2.177.56","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514522103"},{"key":"2024111108000862000_91.2.177.57","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.nrl.2014.12.001","article-title":"Neuromyelitis optica: association with paroxysmal painful tonic spasms","volume":"31","author":"Carnero Contentti","year":"2016","journal-title":"Neurologia"},{"key":"2024111108000862000_91.2.177.58","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314991"},{"key":"2024111108000862000_91.2.177.59","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jns.2016.06.041","article-title":"Pain in patients with transverse myelitis and its relationship to aquaporin 4 antibody status","volume":"368","author":"Kong","year":"2016","journal-title":"J Neurol Sci"},{"key":"2024111108000862000_91.2.177.60","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1116-7"},{"key":"2024111108000862000_91.2.177.61","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-015-0403-8","article-title":"NF\u03baB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG","volume":"12","author":"Walker-Caulfield","year":"2015","journal-title":"J Neuroinflammation"},{"key":"2024111108000862000_91.2.177.62","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.129"},{"key":"2024111108000862000_91.2.177.63","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000289761.64862.ce"},{"key":"2024111108000862000_91.2.177.64","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.832"},{"key":"2024111108000862000_91.2.177.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.10.006"},{"key":"2024111108000862000_91.2.177.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.11.004"},{"key":"2024111108000862000_91.2.177.67","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-3-201002020-00006"},{"key":"2024111108000862000_91.2.177.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.10.015"},{"key":"2024111108000862000_91.2.177.69","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08589-6"},{"key":"2024111108000862000_91.2.177.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.06.012"},{"key":"2024111108000862000_91.2.177.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.01.023"},{"key":"2024111108000862000_91.2.177.72","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-12-j0002.2002"},{"key":"2024111108000862000_91.2.177.73","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2006.02.013"},{"key":"2024111108000862000_91.2.177.74","doi-asserted-by":"crossref","first-page":"476","DOI":"10.7326\/M17-0509","article-title":"Low-dose intravenous immunoglobulin treatment for long-standing complex regional pain syndrome: a randomized trial","volume":"167","author":"Goebel","year":"2017","journal-title":"Ann Intern Med"},{"issue":"11 Suppl 1","key":"2024111108000862000_91.2.177.75","first-page":"II-274","article-title":"Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass","volume":"110","author":"Lazar","year":"2004","journal-title":"Circulation"},{"key":"2024111108000862000_91.2.177.76","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-neuro-072116-031121"},{"key":"2024111108000862000_91.2.177.77","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-10-239","article-title":"Nerve growth factor: from the early discoveries to the potential clinical use","volume":"10","author":"Aloe","year":"2012","journal-title":"J Transl Med"},{"key":"2024111108000862000_91.2.177.78","first-page":"373","article-title":"Anti-nerve growth factor in pain management: current evidence","volume":"9","author":"Chang","year":"2016","journal-title":"J Pain Res"},{"key":"2024111108000862000_91.2.177.79","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2014.10.003"},{"key":"2024111108000862000_91.2.177.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.04.035"},{"key":"2024111108000862000_91.2.177.81","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000831"},{"key":"2024111108000862000_91.2.177.82","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cpdd.345","article-title":"Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date","volume":"6","author":"Pellesi","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2024111108000862000_91.2.177.83","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70251-0"},{"key":"2024111108000862000_91.2.177.84","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/PRBM.S15375","article-title":"The role of psychological interventions in the management of patients with chronic pain","volume":"4","author":"Roditi","year":"2011","journal-title":"Psychol Res Behav Manag"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2018-318556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T16:01:36Z","timestamp":1731340896000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2018-318556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,17]]},"references-count":84,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,1,10]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1136\/jnnp-2018-318556"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2018-318556","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,17]]}}}